Vascular surgery

CES 2021 Mission for the human race, Pulxion's early detection technology is here to save lives

Thursday, January 14, 2021 - 8:04am

Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the team's research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

CES 2021 Mission for the Human Race, Pulxion’s Early Detection Technology Is Here to Save Lives.

Thursday, January 14, 2021 - 4:58am

Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the teams research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

Genuity Science Wins 2021 BIG Innovation Award for Novel Genome Sequencing Approach

Tuesday, January 12, 2021 - 7:11pm

BOSTON, Jan. 12, 2021 /PRNewswire/ -- Genuity Science , a genomics and data-sourcing, analytics and insights organization, today announced that it has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group.

Key Points: 
  • BOSTON, Jan. 12, 2021 /PRNewswire/ -- Genuity Science , a genomics and data-sourcing, analytics and insights organization, today announced that it has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group.
  • The BIG innovation Awards recognize those organizations and people who bring new ideas to life, and change the way we experience the world.
  • Genuity Science's AI technology sifted through a large amount of high-dimensional data without a starting hypothesis, allowing the teams to uncover novel causal connections at the single-cell level.
  • "We are honored to be recognized for our deep learning approach that helped, in part, discover the underlying cause of thoracic aortic aneurysms," said Tom Chittenden, PhD, DPhil, PStat, Chief Data Science Officer, Genuity Science.

Endospan Enrolls First Patient in the TRIOMPHE IDE Study

Tuesday, January 12, 2021 - 2:00pm

Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease, announces the first implant of the NEXUS Aortic Arch Stent Graft System on a patient with a thoracic aortic aneurysm as part of the TRIOMPHE Study in Norfolk, Virginia, January 11, 2021.

Key Points: 
  • Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease, announces the first implant of the NEXUS Aortic Arch Stent Graft System on a patient with a thoracic aortic aneurysm as part of the TRIOMPHE Study in Norfolk, Virginia, January 11, 2021.
  • The TRIOMPHE Study is a multi-arm, multi-center, non-randomized, prospective, clinical study to evaluate the safety and effectiveness of NEXUS in treating thoracic aortic lesions involving the aortic arch.
  • With the first patient enrolled in the TRIOMPHE IDE study, Endospan marks the next crucial milestone towards US approval for the NEXUS Aortic Arch Repair Stent Graft System, said Kevin Mayberry, CEO.
  • The NEXUS is specifically engineered for total endovascular arch repair to address the specific challenges of the aortic arch anatomy.

Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During "J.P. Morgan Week 2021"

Thursday, January 7, 2021 - 12:33pm

DuraGraft is a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries.

Key Points: 
  • DuraGraft is a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries.
  • The use of DuraGraft is associated with the reduction of post-CABG complications associated with graft disease and failure: Myocardial Infarction, Repeat Revascularization, and MACE.
  • Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During "J.P. Morgan Week 2021"

Thursday, January 7, 2021 - 12:33pm

DuraGraft is a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries.

Key Points: 
  • DuraGraft is a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries.
  • The use of DuraGraft is associated with the reduction of post-CABG complications associated with graft disease and failure: Myocardial Infarction, Repeat Revascularization, and MACE.
  • Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Global Vascular Access Devices Market to Grow with Advancements in Cardiovascular Treatment Lines, Says TMR

Thursday, January 7, 2021 - 12:30pm

The growth of the global vascular access devices market has become a function of advancements intravenous cardiovascular treatments.

Key Points: 
  • The growth of the global vascular access devices market has become a function of advancements intravenous cardiovascular treatments.
  • The CAGR of the global vascular access devices market over this forecast period is calculated at 5.8%.
  • The demand for clinical trials related to cardiovascular treatments has also increased, creating increased revenue generation across the global vascular access devices market.
  • Global Vascular Access Devices Market: Key Drivers
    Use of vascular access devices across diagnostic centers has given a thrust to market expansion.

Global Vascular Access Devices Market to Grow with Advancements in Cardiovascular Treatment Lines, Says TMR

Thursday, January 7, 2021 - 12:30pm

The growth of the global vascular access devices market has become a function of advancements intravenous cardiovascular treatments.

Key Points: 
  • The growth of the global vascular access devices market has become a function of advancements intravenous cardiovascular treatments.
  • The CAGR of the global vascular access devices market over this forecast period is calculated at 5.8%.
  • The demand for clinical trials related to cardiovascular treatments has also increased, creating increased revenue generation across the global vascular access devices market.
  • Global Vascular Access Devices Market: Key Drivers
    Use of vascular access devices across diagnostic centers has given a thrust to market expansion.

Study of patients undergoing abdominal aortic aneurysm repair suggests screening guidelines may be inadequate

Tuesday, January 5, 2021 - 2:15pm

Rosemont, Ill., Jan. 05, 2021 (GLOBE NEWSWIRE) -- A retrospective study analyzing approximately 55,000 patients undergoing abdominal aortic aneurysm (AAA) repair suggests current AAA screening guidelines may be inadequate in detecting a significant number of new cases.

Key Points: 
  • Rosemont, Ill., Jan. 05, 2021 (GLOBE NEWSWIRE) -- A retrospective study analyzing approximately 55,000 patients undergoing abdominal aortic aneurysm (AAA) repair suggests current AAA screening guidelines may be inadequate in detecting a significant number of new cases.
  • The study patients were enrolled in the Vascular Quality Initiative between years 2003 and 2019.
  • Screening guidelines derived from the 2005 U.S. Preventive Services Task Force (USPTF) recommendations involve a one-time abdominal ultrasound examination only for men aged 65-75 with a history of smoking.
  • Our study additionally describes the clinical characteristics and outcomes in patients undergoing EVAR and open surgery who did not meet the currently accepted screening guidelines.

Dr. Michael Bardwil, Founder of Texas Vein & Cosmetic Specialists, Voted Best Vein Doctor in Houston 2020

Tuesday, January 5, 2021 - 1:00pm

The most recent highlight came in August 2020, when he was honored to be voted best vein doctor in Houston Texasby Living Magazine's Best of Reader's Choice 2020 Awards.

Key Points: 
  • The most recent highlight came in August 2020, when he was honored to be voted best vein doctor in Houston Texasby Living Magazine's Best of Reader's Choice 2020 Awards.
  • As a vein specialistwith over 25 years of experience in vascular medicine, Dr. Bardwil operates one of the most established and renowned vein clinics in the greater Houston metropolitan area.
  • Unlike many other vein centers that have appeared in the area over the past decade, Texas Vein & Cosmetic Specialists is operated by a board-certified vascular surgeon, Dr. Bardwil.
  • Texas Vein & Cosmetic Specialiststreats patients with vascular problems in both Katy and Houston.